Predictive Oncology (POAI) Financials

Predictive Oncology logo
$5.71 -0.70 (-10.85%)
As of 11/20/2026
Annual Income Statements for Predictive Oncology

Annual Income Statements for Predictive Oncology

This table shows Predictive Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-4.79 -6.53 -6.00 -10 -20 -26 -20 -26 -14 -13 -233
Consolidated Net Income / (Loss)
-4.79 -6.53 -6.00 -10 -19 -26 -20 -26 -14 -13 -233
Net Income / (Loss) Continuing Operations
-4.79 -6.53 -6.00 -10 -19 -26 -20 -26 -12 -10 -233
Total Pre-Tax Income
-4.79 -6.53 -6.06 -8.30 -19 -26 -20 -26 -12 -10 -233
Total Operating Income
-4.40 -6.53 -6.05 -7.86 -23 -25 -20 -26 -12 -10 -181
Total Gross Profit
0.35 0.27 0.51 1.00 0.88 0.81 0.93 1.00 1.02 0.01 0.05
Total Revenue
0.65 0.46 0.65 1.41 1.41 1.25 1.42 1.51 1.63 0.08 0.13
Operating Revenue
0.65 0.46 0.65 1.41 1.41 1.25 1.42 1.51 1.63 0.08 0.13
Total Cost of Revenue
0.30 0.18 0.15 0.42 0.53 0.45 0.49 0.51 0.61 0.08 0.07
Operating Cost of Revenue
0.30 0.18 0.15 0.42 0.53 0.45 0.49 0.51 0.61 0.08 0.07
Total Operating Expenses
4.75 6.80 6.56 8.86 24 26 21 27 13 10 181
Selling, General & Admin Expense
4.25 6.33 5.47 6.49 13 13 14 15 12 7.24 26
Marketing Expense
0.50 0.47 1.10 2.37 1.91 0.58 0.77 1.36 1.49 0.83 0.41
Research & Development Expense
- - - - - - - - - 2.24 2.15
Other Operating Expenses / (Income)
- - - - - - - - - 0.00 152
Total Other Income / (Expense), net
-0.39 -0.00 -0.00 -0.44 3.69 -0.52 0.11 0.30 0.17 0.09 -52
Other Income / (Expense), net
- - -0.00 -0.44 4.21 1.47 0.11 0.30 0.17 0.09 -52
Other Gains / (Losses), net
- - 0.05 -1.78 -0.44 - - -0.01 -0.06 -0.01 -0.01
Net Income / (Loss) Discontinued Operations
- - - - - - - - -1.97 -2.44 -0.24
Basic Earnings per Share
($30.86) ($2.31) ($0.94) ($7.87) $6.86 $2.21 ($0.36) ($6.98) ($3.48) ($34.83) ($13.37)
Weighted Average Basic Shares Outstanding
155.23K 2.82M 6.36M 1.28M 2.87M 11.95M 54.88M 3.69M 4.01M 363.58K 17.43M
Weighted Average Diluted Shares Outstanding
155.23K 2.82M 6.36M 1.28M 2.87M 11.95M 54.88M 79.40M 4.06M 8.93M 5.54M
Weighted Average Basic & Diluted Shares Outstanding
155.23K 2.82M 6.36M 1.28M 2.87M 11.95M 54.88M 79.40M 4.06M 8.93M 5.54M

Quarterly Income Statements for Predictive Oncology

This table shows Predictive Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-4.22 -3.18 -3.09 -2.17 -2.44 -2.07 -78 -151 -7.71 -17 12
Consolidated Net Income / (Loss)
-4.22 -3.18 -3.09 -2.17 -2.44 -2.07 -78 -151 -7.71 -17 12
Net Income / (Loss) Continuing Operations
-3.56 -2.46 -2.13 -2.07 -2.29 -1.98 -77 -151 -7.71 -17 12
Total Pre-Tax Income
-3.56 -2.46 -2.12 -2.07 -2.28 -1.98 -77 -151 -7.71 -17 7.24
Total Operating Income
-3.58 -2.46 -2.16 -2.10 -2.29 -2.66 -2.28 -173 -7.73 -17 6.83
Total Gross Profit
-0.02 0.05 -0.01 -0.02 0.07 -0.02 0.00 0.01 0.03 0.20 0.33
Total Revenue
0.00 0.07 0.00 0.01 0.11 0.00 0.00 0.01 0.04 3.21 7.24
Operating Revenue
0.00 0.07 0.00 0.01 0.11 0.00 0.00 0.01 0.04 3.21 7.24
Total Cost of Revenue
0.02 0.01 0.01 0.03 0.05 0.02 0.00 0.00 0.01 3.01 6.91
Operating Cost of Revenue
0.02 0.01 0.01 0.03 0.05 0.02 0.00 0.00 0.01 3.01 6.91
Total Operating Expenses
3.56 2.52 2.15 2.07 2.35 2.64 2.28 173 7.76 18 -6.49
Selling, General & Admin Expense
2.33 1.83 1.55 1.54 1.83 1.88 2.15 20 2.91 2.74 2.93
Marketing Expense
0.61 0.13 0.07 0.02 0.00 0.27 0.13 0.00 0.01 1.18 1.06
Other Operating Expenses / (Income)
- - - - 0.00 0.00 - - 4.30 13 -10
Total Other Income / (Expense), net
0.02 0.01 0.04 0.03 0.00 0.68 -74 22 0.02 0.12 0.41
Other Income / (Expense), net
0.02 0.01 0.04 0.03 0.00 0.68 -74 22 0.02 0.12 0.41
Other Gains / (Losses), net
-0.00 -0.00 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 4.50
Net Income / (Loss) Discontinued Operations
-0.65 -0.72 -0.96 -0.10 -0.16 -0.09 -1.00 0.01 0.00 0.00 -0.23
Basic Earnings per Share
($1.04) ($0.68) ($7.26) ($5.97) ($5.12) ($0.23) ($107.26) ($8.66) ($0.36) ($0.87) $0.54
Weighted Average Basic Shares Outstanding
4.06M 4.66M 426.42K 363.58K 476.84K 9.11M 724.00K 17.43M 21.18M 19.69M 21.37M
Diluted Earnings per Share
- - - ($5.97) - - ($107.26) ($8.66) - - $0.52
Weighted Average Diluted Shares Outstanding
4.10M 6.67M 6.67M 8.93M 8.93M 10.89M 724.00K 5.54M 10.40M 11.59M 21.96M
Weighted Average Basic & Diluted Shares Outstanding
4.10M 6.67M 6.67M 8.93M 8.93M 10.89M 3.39M 5.54M 10.40M 11.59M 13.65M

Annual Cash Flow Statements for Predictive Oncology

This table details how cash moves in and out of Predictive Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
4.84 -3.09 -1.00 -0.60 -0.01 0.53 28 -6.13 -13 -7.99 10
Net Cash From Operating Activities
-7.49 -4.38 -4.46 -5.29 -8.73 -12 -12 -12 -12 -10 -9.88
Net Cash From Continuing Operating Activities
-7.49 -4.38 -4.46 -5.29 -8.73 -12 -12 -12 -12 -10 -9.88
Net Income / (Loss) Continuing Operations
-4.79 -6.53 -6.00 -10 -19 -26 -20 -26 -12 -10 -233
Consolidated Net Income / (Loss)
-4.79 -6.53 -6.00 -10 -19 -26 -20 -26 -14 -13 -233
Net Income / (Loss) Discontinued Operations
- - - - - - - - -1.97 -2.44 -0.24
Depreciation Expense
0.08 0.08 0.07 0.15 0.70 1.02 1.34 1.31 0.24 0.13 0.13
Amortization Expense
0.22 - 0.00 0.39 2.02 1.25 0.24 - 0.48 0.50 0.56
Non-Cash Adjustments To Reconcile Net Income
0.89 1.62 2.66 3.38 6.06 13 7.06 11 -0.14 -0.30 168
Changes in Operating Assets and Liabilities, net
-3.89 0.45 -1.18 0.88 1.87 -1.21 -1.19 0.87 -0.35 -0.21 54
Net Cash From Investing Activities
-0.06 -0.42 -1.65 -1.11 -0.60 -0.17 -11 -0.48 -0.05 -0.01 -33
Net Cash From Continuing Investing Activities
-0.06 -0.42 -1.65 -1.11 -0.60 -0.17 -11 -0.48 -0.05 -0.01 -33
Purchase of Property, Plant & Equipment
-0.03 -0.03 -0.05 -0.18 -0.01 -0.30 -0.91 -0.42 -0.02 -0.01 0.00
Other Investing Activities, net
0.00 -0.10 -1.88 -0.88 -0.98 0.00 -0.06 - - 0.00 -33
Net Cash From Financing Activities
12 1.71 5.11 5.79 9.32 13 50 6.72 0.15 3.94 52
Net Cash From Continuing Financing Activities
12 1.71 5.11 5.79 9.32 13 50 6.72 0.15 3.94 52
Repayment of Debt
-0.93 - - 0.00 -1.15 -1.45 -4.29 0.00 -0.21 -0.43 -0.16
Repurchase of Common Equity
- - - - - 0.00 -0.01 -0.03 -0.00 -0.87 -4.05
Issuance of Debt
0.25 - 0.00 2.19 2.69 2.76 - 0.00 0.36 0.28 0.26
Issuance of Common Equity
13 1.71 3.81 2.96 5.32 9.95 51 6.74 0.00 4.96 56
Other Financing Activities, net
- - 0.00 0.65 0.12 1.69 3.44 - - 0.00 -0.06
Other Net Changes in Cash
- - - - - - - - -1.66 -1.82 0.54
Cash Interest Paid
- - - 0.00 0.15 0.15 0.69 0.00 0.01 0.01 0.01

Quarterly Cash Flow Statements for Predictive Oncology

This table details how cash moves in and out of Predictive Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-3.53 0.13 -2.25 -2.34 2.37 -2.60 -0.32 11 -3.87 15 126
Net Cash From Operating Activities
-2.71 -2.79 -2.55 -2.05 -0.99 -3.29 -1.65 -3.94 -3.75 21 448
Net Cash From Continuing Operating Activities
-2.71 -2.79 -2.55 -2.05 -0.99 -3.29 -1.65 -3.94 -3.75 21 448
Net Income / (Loss) Continuing Operations
-3.56 -2.46 -2.13 -2.07 -2.29 -1.98 -78 -151 -7.71 -17 14
Consolidated Net Income / (Loss)
-4.22 -3.18 -3.09 -2.17 -2.44 -2.07 -78 -151 -7.71 -17 12
Net Income / (Loss) Discontinued Operations
-0.65 -0.72 -0.96 -0.10 -0.16 -0.09 -0.01 0.01 0.00 - -2.13
Depreciation Expense
0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 -0.05
Amortization Expense
0.12 0.12 0.13 0.13 0.13 0.14 0.14 0.15 0.15 0.16 4.36
Non-Cash Adjustments To Reconcile Net Income
-0.11 -0.02 -0.12 -0.06 -0.27 -0.68 0.36 168 4.93 -20 -80
Changes in Operating Assets and Liabilities, net
0.81 -0.48 -0.45 -0.09 1.40 -0.80 75 -22 -1.15 58 510
Net Cash From Investing Activities
-0.00 - - -0.01 0.00 - - -33 -0.02 -17 -318
Net Cash From Continuing Investing Activities
-0.00 - - -0.01 0.00 - - -33 -0.02 -17 -318
Purchase of Property, Plant & Equipment
-0.00 - - -0.01 0.00 - - - -0.02 -17 -225
Net Cash From Financing Activities
-0.11 3.36 0.89 -0.20 2.50 0.73 1.33 47 -0.10 11 -0.42
Net Cash From Continuing Financing Activities
-0.11 3.36 0.89 -0.20 2.50 0.73 1.33 47 -0.10 11 -0.42
Repayment of Debt
-0.11 -0.04 -0.08 -0.20 0.00 - -0.08 -0.08 -0.08 -0.03 -0.12
Issuance of Common Equity
0.00 3.70 1.26 - 2.58 0.59 1.44 51 0.01 11 -0.30
Other Net Changes in Cash
-0.71 -0.43 -0.60 -0.09 0.85 -0.03 0.00 -0.28 0.00 - -4.03
Cash Interest Paid
0.00 - 0.01 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00

Annual Balance Sheets for Predictive Oncology

This table presents Predictive Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
5.63 2.81 3.62 3.71 22 13 44 26 14 4.97 53
Total Current Assets
5.40 2.61 2.37 1.45 0.80 1.51 29 23 10 2.23 43
Cash & Equivalents
4.86 1.76 0.77 0.16 0.15 0.68 28 22 8.73 0.61 11
Short-Term Investments
0.00 0.38 0.24 - - - - - - 0.00 24
Accounts Receivable
0.04 0.04 0.14 0.23 0.30 0.26 0.35 0.33 0.28 0.03 0.00
Prepaid Expenses
0.27 0.15 0.29 0.32 0.16 0.29 0.51 0.53 0.51 0.32 0.22
Other Current Assets
- - - - - - - - - 0.00 7.23
Other Current Nonoperating Assets
- - - - - - - - 0.08 1.26 0.12
Plant, Property, & Equipment, net
0.14 0.10 0.09 0.18 1.51 3.82 2.51 1.83 0.49 0.35 0.00
Total Noncurrent Assets
0.09 0.10 1.17 2.08 20 7.72 12 0.54 3.85 2.40 10
Long-Term Investments
- - - - - - - - - - 0.00
Noncurrent Note & Lease Receivables
- 0.00 1.07 1.11 - - - - - - 0.00
Other Noncurrent Operating Assets
- - - 0.00 0.73 1.51 0.98 0.29 2.70 2.20 8.26
Other Noncurrent Nonoperating Assets
- - - - - - - - 0.90 0.20 1.85
Total Liabilities & Shareholders' Equity
5.63 2.81 3.62 3.71 22 13 44 26 14 4.97 53
Total Liabilities
1.52 1.88 0.93 3.66 11 10 3.51 3.97 6.15 5.18 5.17
Total Current Liabilities
1.52 1.57 0.93 3.66 11 9.34 3.24 3.88 3.95 3.59 4.27
Short-Term Debt
- - 0.00 - 4.80 4.43 - 0.00 0.15 0.00 0.11
Accounts Payable
0.65 0.22 0.14 0.45 3.16 1.37 1.02 0.94 1.33 1.04 1.15
Accrued Expenses
0.86 1.35 0.79 1.28 2.37 2.59 1.26 2.23 1.54 1.24 1.39
Current Deferred Revenue
0.01 0.01 0.01 0.02 0.04 0.05 0.19 0.60 0.30 - 0.00
Other Current Liabilities
- - 0.00 1.91 0.51 0.89 0.77 0.11 0.45 0.78 0.00
Other Current Nonoperating Liabilities
- - - - - - - - 0.17 0.53 1.61
Total Noncurrent Liabilities
0.00 0.31 0.00 0.00 0.27 1.08 0.27 0.09 2.19 1.58 0.90
Noncurrent Deferred Revenue
- - - - - - - - - - 0.00
Other Noncurrent Operating Liabilities
0.00 0.31 - 0.00 0.27 1.08 0.27 0.09 2.14 1.56 0.00
Other Noncurrent Nonoperating Liabilities
- - - - - - - - 0.06 0.02 0.90
Total Equity & Noncontrolling Interests
4.11 0.92 2.69 0.05 11 2.64 40 22 8.27 -0.20 48
Total Preferred & Common Equity
4.11 0.92 2.69 0.05 11 2.64 40 22 8.27 -0.20 48
Preferred Stock
- - 0.01 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
4.09 0.92 2.68 0.05 11 2.64 40 22 8.27 -0.20 48
Common Stock
45 48 56 63 94 111 168 176 176 180 461
Retained Earnings
-40 -47 -53 -63 -82 -108 -128 -154 -168 -180 -414

Quarterly Balance Sheets for Predictive Oncology

This table presents Predictive Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
18 11 11 7.50 5.87 3.44 3.14 45 100 686
Total Current Assets
14 6.56 6.88 4.57 3.49 1.22 1.10 38 56 208
Cash & Equivalents
12 5.20 5.33 3.08 3.09 0.51 0.18 6.93 22 148
Short-Term Investments
- - - - - - - 20 - 15
Accounts Receivable
0.54 0.51 0.39 0.46 0.06 0.02 0.03 0.66 3.32 1.03
Prepaid Expenses
0.62 0.41 0.60 0.44 0.20 0.60 0.84 0.34 0.87 1.90
Other Current Assets
- - - - - - - 9.44 30 42
Other Current Nonoperating Assets
- - - 0.08 0.10 0.05 0.01 - - 0.00
Plant, Property, & Equipment, net
1.39 1.09 0.91 0.40 0.32 0.28 0.25 0.22 17 367
Total Noncurrent Assets
3.25 2.95 2.79 2.53 2.07 1.93 1.78 7.41 27 109
Noncurrent Note & Lease Receivables
- - - - - - - - - 4.32
Other Noncurrent Operating Assets
2.99 2.71 2.55 2.31 2.01 1.87 1.73 7.41 27 105
Other Noncurrent Nonoperating Assets
- - - 0.00 0.00 0.00 0.00 - - 0.00
Total Liabilities & Shareholders' Equity
18 11 11 7.50 5.87 3.44 3.14 45 100 686
Total Liabilities
6.52 6.55 6.49 5.53 6.01 5.09 81 4.95 66 640
Total Current Liabilities
4.17 4.52 4.62 3.82 4.61 3.85 79 4.23 39 157
Short-Term Debt
0.26 0.04 0.28 0.20 - 0.27 0.19 0.03 0.41 37
Accounts Payable
1.17 1.73 1.56 1.14 1.21 1.35 2.72 1.35 2.49 0.63
Accrued Expenses
1.81 1.90 1.95 1.52 2.42 1.14 1.13 1.39 1.43 3.02
Current Deferred Revenue
0.37 0.30 0.27 0.26 0.15 0.15 0.15 0.79 - 101
Other Current Liabilities
0.56 0.54 0.56 0.50 0.51 0.60 75 0.68 34 15
Other Current Nonoperating Liabilities
- - - 0.21 0.31 0.34 0.31 - - 0.00
Total Noncurrent Liabilities
2.34 2.03 1.87 1.71 1.41 1.24 1.08 0.72 28 483
Noncurrent Deferred Revenue
- - - - - - - - 27 468
Other Noncurrent Operating Liabilities
2.34 2.03 1.87 1.71 1.41 1.24 1.08 0.72 0.54 14
Other Noncurrent Nonoperating Liabilities
- - - 0.00 0.00 0.00 0.00 - - 0.00
Total Equity & Noncontrolling Interests
12 4.05 4.09 1.97 -0.15 -1.65 -77 40 34 46
Total Preferred & Common Equity
12 4.05 4.09 1.97 -0.15 -1.65 -77 40 34 46
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
12 4.05 4.09 1.97 -0.15 -1.65 -77 40 34 46
Common Stock
176 176 179 180 183 183 185 462 472 473
Retained Earnings
-164 -172 -175 -178 -183 -185 -263 -421 -438 -427

Annual Metrics And Ratios for Predictive Oncology

This table displays calculated financial ratios and metrics derived from Predictive Oncology's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
3,312,863.00 3,804,860.00 6,282,761.00 14,091,748.00 3,887,956.00 17,676,621.00 65,576,334.00 78,753,475.00 4,063,081.00 6,666,993.00 3,393,516.00
DEI Adjusted Shares Outstanding
44.00 1,268.00 2,094.00 4,697.00 12,960.00 58,922.00 218,588.00 262,512.00 270,872.00 444,466.00 3,393,516.00
DEI Earnings Per Adjusted Shares Outstanding
-108,875.68 -5,146.70 -2,866.77 -2,147.43 -1,518.57 -448.71 -89.93 -98.04 -51.63 -28.49 -68.69
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-31.23% -30.24% 43.45% 115.57% -0.01% -11.28% 13.45% 5.97% 8.12% -94.79% 47.72%
EBITDA Growth
33.25% -57.09% 7.12% -29.83% -102.17% -37.60% 13.34% -30.35% 54.02% 14.63% -2,322.08%
EBIT Growth
31.85% -48.33% 7.19% -37.09% -122.06% -29.56% 14.94% -26.64% 53.55% 14.55% -2,179.84%
NOPAT Growth
31.97% -48.33% 7.24% -29.86% -188.05% -11.99% 19.45% -27.44% 53.45% 14.97% -1,655.79%
Net Income Growth
29.90% -36.23% 8.01% -68.02% -92.25% -33.49% 24.06% -30.93% 45.67% 9.44% -1,740.56%
EPS Growth
29.90% 92.51% 59.31% -68.02% 187.17% -67.78% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth
-122.08% 41.48% -1.79% -18.57% -65.14% -40.37% 0.40% -1.33% 4.74% 14.26% 2.25%
Free Cash Flow Firm Growth
-133.19% 41.04% -74.77% 48.01% -757.30% 74.02% -141.38% 70.68% -32.07% 15.33% -2,053.00%
Invested Capital Growth
83.82% -64.72% 237.23% -106.47% 14,708.29% -59.71% 88.60% -102.53% -245.37% -63.07% 831.68%
Revenue Q/Q Growth
2.75% -8.74% 14.07% 6.91% 2.61% -4.11% 14.76% -6.98% -8.05% -71.45% -92.47%
EBITDA Q/Q Growth
-7.09% 19.22% -8.10% -27.12% -131.30% 11.53% 4.42% 2.22% 35.36% 2.96% -176.81%
EBIT Q/Q Growth
-2.66% 19.03% -7.96% -33.15% -97.75% 10.77% 4.94% 2.24% 33.26% -1.98% -175.20%
NOPAT Q/Q Growth
-2.66% 19.03% -7.90% -26.07% -65.50% -3.17% 16.32% 2.24% 33.15% -1.40% -1,550.82%
Net Income Q/Q Growth
2.09% 18.99% -7.00% -29.88% -95.58% 7.19% 13.85% -0.62% 24.10% 9.35% -176.39%
EPS Q/Q Growth
2.09% 4.94% -4.44% -29.88% 314.38% 218.18% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-53.87% 33.15% -16.92% 1.93% -22.05% 3.86% -13.37% 3.95% 4.16% 6.22% -11.48%
Free Cash Flow Firm Q/Q Growth
-73.71% 35.29% -30.74% 52.96% -20.72% 31.67% -163.12% 65.20% 8.88% -3.42% -305.27%
Invested Capital Q/Q Growth
61.25% 1.62% 476.66% -102.84% -22.99% -58.77% 100.60% -107.28% -30,292.89% -118.91% 116.33%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
53.54% 60.21% 77.39% 70.55% 62.32% 64.29% 65.72% 66.45% 62.57% 7.70% 42.03%
EBITDA Margin
-626.87% -1,411.55% -914.00% -550.45% -1,112.93% -1,726.17% -1,318.64% -1,622.05% -689.80% -11,301.44% -185,303.87%
Operating Margin
-672.36% -1,429.59% -924.43% -556.89% -1,604.23% -2,025.12% -1,437.95% -1,729.28% -744.47% -12,149.14% -144,404.49%
EBIT Margin
-672.36% -1,429.59% -924.93% -588.19% -1,306.20% -1,907.55% -1,430.22% -1,709.27% -734.33% -12,042.15% -185,853.48%
Profit (Net Income) Margin
-732.10% -1,429.59% -916.72% -714.51% -1,373.71% -2,066.99% -1,383.65% -1,709.62% -859.13% -14,932.31% -186,053.45%
Tax Burden Percent
100.00% 100.00% 99.11% 121.48% 102.32% 100.00% 96.74% 100.02% 117.00% 124.00% 100.11%
Interest Burden Percent
108.88% 100.00% 100.00% 100.00% 102.78% 108.36% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% -1,858.47% -700.09% -201.06% -159.41% -154.94% -309.99% 0.00% 0.00% -2,329.42%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% -1,746.71% 81.20% -358.97% -353.07% -111.11% -280.10% 0.00% 0.00% -1,748.36%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 1,526.41% -34.71% -142.60% -213.73% 63.31% 227.01% 0.00% 0.00% 1,348.27%
Return on Equity (ROE)
682.65% -259.15% -332.06% -734.79% -343.66% -373.14% -91.62% -82.98% -93.11% -313.90% -981.16%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -424.99% 0.00% -200.53% -74.28% -216.33% 0.00% 0.00% 0.00% -1,119.20%
Operating Return on Assets (OROA)
-134.68% -154.65% -188.34% -226.45% -141.37% -134.82% -71.51% -74.04% -59.54% -105.35% -804.84%
Return on Assets (ROA)
-146.65% -154.65% -186.67% -275.09% -148.68% -146.09% -69.18% -74.06% -69.66% -130.63% -805.71%
Return on Common Equity (ROCE)
691.96% -258.14% -331.32% -732.85% -342.57% -372.15% -91.62% -82.98% -93.10% -313.83% -981.12%
Return on Equity Simple (ROE_SIMPLE)
-116.48% -706.52% -223.00% 0.00% -172.65% -979.47% -48.82% -118.25% -169.06% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.08 -4.57 -4.24 -5.50 -16 -18 -14 -18 -8.48 -7.21 -127
NOPAT Margin
-470.66% -1,000.71% -647.10% -389.82% -1,122.96% -1,417.59% -1,006.56% -1,210.50% -521.13% -8,504.40% -101,083.14%
Net Nonoperating Expense Percent (NNEP)
-86.95% -55.90% -111.76% -781.29% 157.91% 193.66% -43.82% -29.89% -35.04% -100.53% -581.06%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -100.72% 3,559.92% -264.80%
Cost of Revenue to Revenue
46.46% 39.79% 22.61% 29.45% 37.68% 35.71% 34.28% 33.55% 37.43% 92.30% 57.97%
SG&A Expenses to Revenue
648.89% 1,387.29% 834.57% 459.61% 902.64% 1,014.45% 959.45% 990.34% 715.68% 8,531.57% 20,692.47%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,642.86% 1,713.88%
Operating Expenses to Revenue
725.91% 1,489.81% 1,001.83% 627.44% 1,666.55% 2,089.41% 1,503.67% 1,795.73% 807.04% 12,156.84% 144,446.52%
Earnings before Interest and Taxes (EBIT)
-4.40 -6.53 -6.06 -8.30 -18 -24 -20 -26 -12 -10 -233
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-4.10 -6.44 -5.99 -7.77 -16 -22 -19 -24 -11 -9.58 -232
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 11.54 2.36 163.16 0.91 4.90 1.55 1.11 1.62 0.00 0.51
Price to Tangible Book Value (P/TBV)
0.00 12.91 2.45 0.00 0.00 0.00 2.12 1.12 1.66 0.00 0.51
Price to Revenue (P/Rev)
0.00 23.34 9.69 6.18 7.19 10.34 43.94 16.04 8.21 64.46 193.67
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 3.18 0.00 0.93 2.61 2.84 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 18.63 8.16 6.07 10.50 13.34 24.09 1.38 2.94 57.25 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.43 1.68 0.00 0.00 0.02 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
2.80 -1.39 -0.87 -0.43 0.40 0.61 -0.57 -0.81 -1.05 -1.34 -0.77
Leverage Ratio
-4.66 1.68 1.78 2.67 2.31 2.55 1.32 1.12 1.34 2.40 1.22
Compound Leverage Factor
-5.07 1.68 1.78 2.67 2.38 2.77 1.32 1.12 1.34 2.40 1.22
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 29.92% 62.65% 0.00% 0.00% 1.79% 0.00% 0.23%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 29.92% 62.65% 0.00% 0.00% 1.79% 0.00% 0.23%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.27% 0.00% 0.22% 0.01% 0.00% 0.00% 0.01% -0.39% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
99.54% 99.91% 99.73% 100.00% 69.85% 37.34% 100.00% 100.00% 98.20% 100.39% 99.77%
Debt to EBITDA
0.00 0.00 0.00 0.00 -0.31 -0.21 0.00 0.00 -0.01 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 -0.30 -0.17 0.00 0.00 0.76 0.00 0.15
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 -0.30 -0.25 0.00 0.00 -0.02 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 -0.29 -0.21 0.00 0.00 1.01 0.00 0.28
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 -27.12 -21.26 -30.11 -7.81 -17.53 5.81 -7.05 -17.10 -57.26 -21.78
Noncontrolling Interest Sharing Ratio
-1.36% 0.39% 0.22% 0.26% 0.32% 0.26% 0.00% 0.00% 0.01% 0.02% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.55 1.66 2.54 0.40 0.07 0.16 9.09 6.02 2.55 0.62 10.02
Quick Ratio
3.22 1.39 1.95 0.24 0.04 0.10 8.81 5.77 2.28 0.18 8.26
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-6.93 -4.09 -7.14 -3.71 -32 -8.27 -20 -5.85 -7.73 -6.55 -141
Operating Cash Flow to CapEx
-23,059.11% -13,374.36% -9,890.12% -2,975.24% 0.00% -11,667.59% -1,341.01% -2,946.35% -54,725.63% -106,236.42% 0.00%
Free Cash Flow to Firm to Interest Expense
-17.73 -1,362,330.57 0.00 0.00 -62.03 -4.14 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-19.15 -1,460,480.00 0.00 0.00 -17.01 -6.14 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-19.24 -1,471,400.00 0.00 0.00 -16.72 -6.19 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.20 0.11 0.20 0.39 0.11 0.07 0.05 0.04 0.08 0.01 0.00
Accounts Receivable Turnover
13.66 11.83 7.42 7.63 5.33 4.52 4.65 4.39 5.35 0.54 3.78
Inventory Turnover
1.01 0.72 0.55 1.64 2.47 1.86 1.44 1.23 1.34 0.00 0.00
Fixed Asset Turnover
3.89 3.79 6.92 10.53 1.67 0.47 0.45 0.69 1.40 0.20 0.44
Accounts Payable Turnover
0.21 0.42 0.82 1.42 0.30 0.20 0.41 0.51 0.54 0.07 0.05
Days Sales Outstanding (DSO)
26.73 30.86 49.17 47.85 68.48 80.73 78.50 83.09 68.26 670.93 96.54
Days Inventory Outstanding (DIO)
359.68 506.39 662.29 222.16 147.98 195.76 253.77 295.62 272.99 0.00 0.00
Days Payable Outstanding (DPO)
1,708.00 874.74 444.49 257.29 1,235.86 1,847.77 897.03 710.06 682.27 5,544.72 7,250.05
Cash Conversion Cycle (CCC)
-1,321.59 -337.49 266.97 12.71 -1,019.40 -1,571.28 -564.76 -331.35 -341.01 -4,873.80 -7,153.51
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.74 -1.22 1.68 -0.11 16 6.40 12 -0.31 -1.06 -1.72 13
Invested Capital Turnover
-0.25 -0.46 2.87 1.80 0.18 0.11 0.15 0.26 -2.39 -0.06 0.02
Increase / (Decrease) in Invested Capital
3.85 -0.48 2.91 -1.79 16 -9.48 5.67 -12 -0.75 -0.67 14
Enterprise Value (EV)
0.00 8.51 5.34 8.56 15 17 34 2.08 4.79 4.86 -11
Market Capitalization
0.00 11 6.35 8.72 10 13 62 24 13 5.47 24
Book Value per Share
$26.37 $0.24 $0.43 $0.00 $2.88 $0.15 $0.61 $0.28 $2.04 ($0.03) $14.06
Tangible Book Value per Share
$25.76 $0.22 $0.41 ($0.06) ($2.09) ($0.20) $0.45 $0.27 $1.98 ($0.03) $14.06
Total Capital
4.11 0.92 2.69 0.05 16 7.07 40 22 8.42 -0.20 48
Total Debt
0.00 0.00 0.00 0.00 4.80 4.43 0.00 0.00 0.15 0.00 0.11
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-4.86 -2.15 -1.01 -0.16 4.64 3.75 -28 -22 -8.58 -0.61 -35
Capital Expenditures (CapEx)
0.03 0.03 0.05 0.18 -0.15 0.11 0.91 0.42 0.02 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.98 -1.11 0.43 -2.37 -5.43 -4.07 -1.98 -2.59 -2.45 -1.98 3.38
Debt-free Net Working Capital (DFNWC)
3.88 1.03 1.44 -2.20 -5.28 -3.39 26 19 6.28 -1.37 39
Net Working Capital (NWC)
3.88 1.03 1.44 -2.20 -10 -7.82 26 19 6.13 -1.37 39
Net Nonoperating Expense (NNE)
1.71 1.96 1.77 4.58 3.54 8.13 5.36 7.51 5.50 5.45 106
Net Nonoperating Obligations (NNO)
-4.86 -2.15 -1.01 -0.16 4.64 3.75 -28 -22 -9.33 -1.52 -35
Total Depreciation and Amortization (D&A)
0.30 0.08 0.07 0.53 2.73 2.27 1.59 1.31 0.72 0.63 0.69
Debt-free, Cash-free Net Working Capital to Revenue
-149.48% -244.13% 65.31% -167.62% -384.73% -324.94% -139.71% -172.32% -150.57% -2,333.76% 2,698.31%
Debt-free Net Working Capital to Revenue
592.66% 226.50% 219.73% -156.13% -374.04% -270.77% 1,845.44% 1,293.78% 385.69% -1,612.37% 30,818.78%
Net Working Capital to Revenue
592.66% 226.50% 219.73% -156.13% -713.79% -624.68% 1,845.44% 1,293.78% 376.45% -1,612.37% 30,732.62%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($6,150.00) ($462.00) ($244.00) ($158.00) ($137.20) $44.20 $7.20 ($7.00) ($3.48) ($34.80) ($13.37)
Adjusted Weighted Average Basic Shares Outstanding
9.98K 32.45K 59.02K 78.96K 292.39K 2.44M 3.30M 3.65M 4.01M 363.58K 17.43M
Adjusted Diluted Earnings per Share
($6,150.00) ($462.00) ($244.00) ($158.00) ($137.20) $44.20 $7.20 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
9.98K 32.45K 59.02K 78.96K 292.39K 2.44M 3.30M 3.97M 4.06M 595.44K 5.54M
Adjusted Basic & Diluted Earnings per Share
($6,150.00) ($462.00) ($244.00) ($158.00) ($137.20) $44.20 $7.20 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
776.00 14.12K 31.82K 64.08K 143.51K 597.51K 2.74M 3.97M 4.06M 595.44K 5.54M
Normalized Net Operating Profit after Tax (NOPAT)
-3.08 -4.57 -4.24 -5.50 -9.64 -8.74 -9.43 -11 -8.48 -7.21 -127
Normalized NOPAT Margin
-470.66% -1,000.71% -647.10% -389.82% -683.08% -697.81% -663.77% -709.91% -521.13% -8,504.40% -101,083.14%
Pre Tax Income Margin
-732.10% -1,429.59% -924.93% -588.19% -1,342.56% -2,066.99% -1,430.22% -1,709.27% -734.33% -12,042.15% -185,853.48%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-11.26 -2,175,337.00 0.00 0.00 -35.92 -11.96 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-7.88 -1,522,735.90 0.00 0.00 -30.88 -8.89 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-11.34 -2,186,257.00 0.00 0.00 -35.63 -12.02 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-7.96 -1,533,655.90 0.00 0.00 -30.59 -8.94 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.06% -0.11% -0.01% -6.88% -1.74%

Quarterly Metrics And Ratios for Predictive Oncology

This table displays calculated financial ratios and metrics derived from Predictive Oncology's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
4,062,853.00 4,101,776.00 6,666,993.00 6,666,993.00 8,931,621.00 8,931,621.00 10,892,429.00 3,393,516.00 5,539,267.00 10,404,641.00 11,591,124.00
DEI Adjusted Shares Outstanding
270,857.00 273,452.00 444,466.00 444,466.00 595,441.00 595,441.00 726,162.00 3,393,516.00 5,539,267.00 10,404,641.00 11,591,124.00
DEI Earnings Per Adjusted Shares Outstanding
-15.58 -11.63 -6.96 -4.88 -4.10 -3.48 -106.93 -44.48 -1.39 -1.65 0.99
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-97.97% -86.28% -99.42% -96.02% 2,170.69% -96.01% -7.40% -1.34% -67.99% 119,772.93% 0.00%
EBITDA Growth
-7.13% 38.56% 33.28% -4.05% 37.92% 21.42% -3,840.68% -7,800.27% -255.53% -841.88% 114.99%
EBIT Growth
-4.14% 37.42% 22.35% -10.61% 35.91% 19.46% -3,555.42% -7,189.84% -237.54% -770.00% 109.45%
NOPAT Growth
-3.38% 37.75% 21.12% -7.28% 36.15% -7.92% -51.81% -8,135.84% -237.93% -551.46% 527.29%
Net Income Growth
-23.29% 18.92% 2.17% 37.57% 42.10% 34.92% -2,409.20% -6,856.60% -215.57% -731.02% 114.81%
EPS Growth
0.00% 0.00% 0.00% 37.57% 0.00% 0.00% 0.00% -45.06% 0.00% 0.00% 100.48%
Operating Cash Flow Growth
20.95% 21.82% -23.67% 24.61% 63.62% -17.90% 35.03% -91.95% -280.02% 740.91% 51,640.63%
Free Cash Flow Firm Growth
-114.92% -131.99% -131.92% -29.72% 121.76% -48.13% 10,250.12% -16,757.57% -6,960.47% -2,055.93% -84.48%
Invested Capital Growth
-2,487.00% -1,537.25% -22,540.14% -63.07% -173.25% -66.88% -9,708.89% 831.68% 534.96% 882.84% -6.19%
Revenue Q/Q Growth
-97.80% 1,284.42% -94.19% 125.03% 1,154.66% -97.57% 34.90% 139.75% 307.09% 9,004.79% 125.29%
EBITDA Q/Q Growth
-85.98% 32.57% 14.52% 2.93% -10.96% 14.66% -4,186.69% -94.61% 95.01% -126.09% 167.81%
EBIT Q/Q Growth
-90.36% 31.10% 13.49% 2.52% -10.29% 13.41% -3,826.44% -94.40% 94.89% -123.19% 142.08%
NOPAT Q/Q Growth
-83.27% 31.19% 12.34% 2.95% -9.07% -16.30% -23.31% -5,165.12% 95.52% -124.20% 156.27%
Net Income Q/Q Growth
-21.39% 24.59% 2.72% 29.89% -12.60% 15.24% -3,650.46% -94.37% 94.89% -123.19% 166.86%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.52% -3.13% 8.91% 19.33% 51.99% -234.21% 49.80% -138.32% 4.95% 663.65% 2,020.90%
Free Cash Flow Firm Q/Q Growth
-133.66% 43.02% 11.37% -9.94% 139.20% -487.78% 6,172.95% -282.59% 84.05% -21.86% 144.14%
Invested Capital Q/Q Growth
-4.74% 13.09% 18.17% -118.91% -75.50% 46.92% -4,709.80% 116.33% 4.33% -4.46% -752.45%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
-361.77% 79.39% -186.08% -250.51% 59.10% -579.38% -130.96% 89.31% 80.83% 6.27% 4.58%
EBITDA Margin
-70,211.88% -3,419.66% -50,316.61% -21,705.22% -1,919.64% -67,382.14% -2,141,200.64% -1,738,099.16% -21,320.64% -529.44% 159.35%
Operating Margin
-73,734.75% -3,664.64% -55,296.75% -23,848.92% -2,073.29% -99,174.79% -90,654.06% -1,990,880.06% -21,887.46% -538.98% 94.24%
EBIT Margin
-73,350.70% -3,650.57% -54,365.45% -23,550.48% -2,070.18% -73,730.20% -2,146,026.34% -1,740,147.36% -21,829.04% -535.11% 99.96%
Profit (Net Income) Margin
-86,843.21% -4,730.15% -79,208.86% -24,676.91% -2,214.55% -77,198.43% -2,146,264.32% -1,740,027.96% -21,831.56% -535.18% 158.82%
Tax Burden Percent
118.39% 129.57% 145.70% 104.78% 106.97% 104.70% 100.01% 99.99% 100.01% 100.01% 158.89%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -32,115.38% -152.28% -224.84% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -31,951.37% -136.96% -177.49% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24,639.64% 102.42% 117.49% 0.00%
Return on Equity (ROE)
-130.76% -149.36% -205.17% -313.90% -557.26% -801.26% 223.52% -7,475.75% -49.86% -107.35% 1,054.88%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,119.20% -1,115.80% -1,233.76% 0.00%
Operating Return on Assets (OROA)
-5,728.81% -224.40% -1,258.61% -206.02% -47.83% -17,505.93% -671,684.55% -7,535.75% -42.97% -33.64% 3.05%
Return on Assets (ROA)
-6,782.60% -290.76% -1,833.76% -215.88% -51.17% -18,329.40% -671,759.03% -7,535.24% -42.97% -33.64% 4.84%
Return on Common Equity (ROCE)
-130.75% -149.35% -205.14% -313.83% -557.03% -800.74% 223.52% -7,475.50% -49.86% -107.34% 1,054.93%
Return on Equity Simple (ROE_SIMPLE)
-364.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.51 -1.73 -1.51 -1.47 -1.60 -1.86 -2.30 -121 -5.41 -12 6.83
NOPAT Margin
-51,614.32% -2,565.25% -38,707.72% -16,694.24% -1,451.30% -69,422.36% -63,457.84% -1,393,616.04% -15,321.22% -377.28% 94.24%
Net Nonoperating Expense Percent (NNEP)
-14.41% -14.69% -21.97% -12.94% -20.96% -8.33% -6,146.85% -164.01% -15.32% -47.35% 7.32%
Return On Investment Capital (ROIC_SIMPLE)
-61.28% -39.47% -69.93% 724.43% 1,098.06% 134.15% 2.97% -252.76% -13.43% -35.20% 8.21%
Cost of Revenue to Revenue
461.77% 20.61% 286.08% 350.51% 40.90% 679.38% 230.96% 10.69% 19.17% 93.73% 95.42%
SG&A Expenses to Revenue
47,872.87% 2,713.81% 39,551.34% 17,512.37% 1,657.33% 69,934.94% 72,224.30% 226,048.28% 8,227.24% 85.10% 40.42%
R&D to Revenue
12,970.05% 830.71% 13,699.41% 5,885.44% 471.77% 18,632.18% 14,609.09% 6,900.44% 1,550.35% 15.31% 0.00%
Operating Expenses to Revenue
73,372.97% 3,744.04% 55,110.67% 23,598.41% 2,132.39% 98,595.41% 90,523.11% 1,990,969.37% 21,968.29% 545.25% -89.66%
Earnings before Interest and Taxes (EBIT)
-3.56 -2.46 -2.12 -2.07 -2.28 -1.98 -78 -151 -7.71 -17 7.24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.41 -2.30 -1.97 -1.91 -2.12 -1.81 -77 -151 -7.53 -17 12
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.56 1.04 2.67 0.00 0.00 0.00 0.00 0.51 0.22 2.32 2.85
Price to Tangible Book Value (P/TBV)
2.72 1.11 3.01 0.00 0.00 0.00 0.00 0.51 0.22 2.32 2.85
Price to Revenue (P/Rev)
7.44 4.40 17.68 64.46 71.35 4.45 6.20 193.67 178.46 24.17 12.54
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.57 0.00
Enterprise Value to Revenue (EV/Rev)
3.74 0.00 7.98 57.25 55.13 4.31 6.21 0.00 0.00 17.59 0.54
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.87 0.01
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.01 0.07 0.10 0.00 0.00 -0.16 0.00 0.00 0.00 0.01 0.80
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.05 -1.05 -1.06 -1.34 -2.06 -2.05 0.03 -0.77 -0.75 -0.66 4.10
Leverage Ratio
1.58 1.68 1.88 2.40 4.21 5.75 -0.14 1.22 1.27 3.20 -22.12
Compound Leverage Factor
1.58 1.68 1.88 2.40 4.21 5.75 -0.14 1.22 1.27 3.20 -22.12
Debt to Total Capital
0.93% 6.34% 9.05% 0.00% 0.00% -19.13% -0.24% 0.23% 0.07% 1.20% 44.36%
Short-Term Debt to Total Capital
0.93% 6.34% 9.05% 0.00% 0.00% -19.13% -0.24% 0.23% 0.07% 1.20% 44.36%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.02% 0.02% 0.04% -0.39% -0.54% -0.06% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
99.05% 93.65% 90.91% 100.39% 100.54% 119.19% 100.24% 99.77% 99.93% 98.80% 55.64%
Debt to EBITDA
0.00 -0.03 -0.02 0.00 0.00 -0.03 0.00 0.00 0.00 0.00 -0.22
Net Debt to EBITDA
0.43 0.47 0.29 0.00 0.00 0.03 0.00 0.15 0.11 0.09 0.77
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 -0.04 -0.03 0.00 0.00 -0.04 -0.02 0.00 0.00 0.00 -0.27
Net Debt to NOPAT
0.60 0.67 0.41 0.00 0.00 0.03 0.00 0.28 0.21 0.15 0.94
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-22.51 -23.19 -33.49 -51.85 -43.75 -76.82 -228.22 -16.67 -11.63 -5.73 -0.61
Noncontrolling Interest Sharing Ratio
0.01% 0.01% 0.01% 0.02% 0.04% 0.06% 0.00% 0.00% 0.00% 0.00% -0.01%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.45 1.49 1.20 0.62 0.76 0.32 0.01 10.02 8.89 1.45 1.33
Quick Ratio
1.26 1.24 0.93 0.18 0.68 0.14 0.00 8.26 6.58 0.65 1.05
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-1.44 -0.82 -0.73 -0.80 0.31 -1.22 74 -135 -22 -26 12
Operating Cash Flow to CapEx
-89,369.66% 0.00% 0.00% -31,698.13% 0.00% 0.00% 0.00% 0.00% -17,840.11% 123.49% 198.87%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.08 0.06 0.02 0.01 0.02 0.24 0.31 0.00 0.00 0.06 0.03
Accounts Receivable Turnover
3.52 2.37 0.59 0.54 0.67 8.12 6.80 3.78 0.14 1.95 19.82
Inventory Turnover
1.24 0.76 0.59 0.00 0.41 2.79 3.14 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.97 0.79 0.33 0.20 0.27 2.79 5.07 0.44 0.19 0.37 0.06
Accounts Payable Turnover
0.32 0.28 0.24 0.07 0.07 0.59 0.44 0.05 0.03 1.58 5.94
Days Sales Outstanding (DSO)
103.81 153.91 619.58 670.93 546.04 44.95 53.71 96.54 2,610.03 187.08 18.41
Days Inventory Outstanding (DIO)
293.28 480.16 617.93 0.00 881.10 130.68 116.40 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
1,125.18 1,286.13 1,511.60 5,544.72 5,320.24 622.36 828.33 7,250.05 13,632.79 231.37 61.41
Cash Conversion Cycle (CCC)
-728.08 -652.05 -274.09 -4,873.80 -3,893.09 -446.73 -658.22 -7,153.51 -11,022.76 -44.29 -43.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1.11 -0.96 -0.79 -1.72 -3.02 -1.60 -77 13 13 13 -82
Invested Capital Turnover
-2.43 -1.90 -0.75 -0.06 -0.09 -1.30 -0.04 0.02 0.01 0.60 -0.13
Increase / (Decrease) in Invested Capital
-1.06 -0.90 -0.78 -0.67 -1.92 -0.64 -76 14 16 14 -4.78
Enterprise Value (EV)
5.20 -0.79 2.37 4.86 10 7.17 10 -11 -18 57 5.64
Market Capitalization
10 4.27 5.25 5.47 14 7.41 10 24 8.97 79 132
Book Value per Share
$1.00 $1.00 $0.29 ($0.03) ($0.02) ($0.19) ($7.11) $14.06 $11.87 $3.27 $3.99
Tangible Book Value per Share
$0.94 $0.94 $0.26 ($0.03) ($0.03) ($0.19) ($7.11) $14.06 $11.87 $3.27 $3.99
Total Capital
4.09 4.37 2.16 -0.20 -0.15 -1.39 -77 48 40 34 83
Total Debt
0.04 0.28 0.20 0.00 0.00 0.27 0.19 0.11 0.03 0.41 37
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-5.16 -5.05 -2.88 -0.61 -3.09 -0.24 0.01 -35 -27 -21 -126
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.02 17 225
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.11 -2.79 -2.13 -1.98 -4.21 -2.86 -78 3.38 6.23 -4.11 -75
Debt-free Net Working Capital (DFNWC)
2.08 2.54 0.95 -1.37 -1.12 -2.36 -78 39 33 18 88
Net Working Capital (NWC)
2.04 2.27 0.75 -1.37 -1.12 -2.62 -78 39 33 17 51
Net Nonoperating Expense (NNE)
1.71 1.46 1.58 0.70 0.84 0.21 75 30 2.30 5.08 -4.68
Net Nonoperating Obligations (NNO)
-5.16 -5.05 -2.75 -1.52 -2.88 0.05 0.30 -35 -27 -21 -128
Total Depreciation and Amortization (D&A)
0.15 0.16 0.16 0.16 0.17 0.17 0.17 0.18 0.18 0.18 4.30
Debt-free, Cash-free Net Working Capital to Revenue
-223.64% -287.54% -717.82% -2,333.76% -2,213.03% -171.96% -4,709.13% 2,698.31% 12,396.94% -126.09% -714.63%
Debt-free Net Working Capital to Revenue
149.55% 262.24% 318.57% -1,612.37% -590.24% -141.56% -4,698.21% 30,818.78% 66,406.06% 545.33% 837.34%
Net Working Capital to Revenue
146.82% 233.68% 252.67% -1,612.37% -590.24% -157.51% -4,709.47% 30,732.62% 66,351.95% 532.65% 486.20%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.04) ($0.68) ($7.20) ($89.55) ($5.10) ($0.23) ($107.25) ($8.66) ($0.36) ($0.87) $0.54
Adjusted Weighted Average Basic Shares Outstanding
4.06M 4.66M 426.42K 24.24K 476.82K 9.11M 724.00K 17.43M 21.18M 19.69M 21.37M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 ($89.55) $0.00 $0.00 $0.00 ($8.66) $0.00 $0.00 $0.52
Adjusted Weighted Average Diluted Shares Outstanding
4.10M 6.67M 444.47K 595.44K 595.44K 10.89M 3.39M 5.54M 10.40M 11.59M 21.96M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($89.55) $0.00 $0.00 $0.00 ($8.66) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
4.10M 6.67M 444.47K 595.44K 595.44K 10.89M 3.39M 5.54M 10.40M 11.59M 13.65M
Normalized Net Operating Profit after Tax (NOPAT)
-2.51 -1.73 -1.51 -1.47 -1.60 -1.86 -2.30 -121 -5.41 -12 4.78
Normalized NOPAT Margin
-51,614.32% -2,565.25% -38,707.72% -16,694.24% -1,451.30% -69,422.36% -63,457.84% -1,393,616.04% -15,321.22% -377.28% 65.97%
Pre Tax Income Margin
-73,350.70% -3,650.57% -54,365.45% -23,550.48% -2,070.18% -73,730.20% -2,146,026.34% -1,740,147.36% -21,829.04% -535.11% 99.96%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -4.10% -6.25% -6.88% -8.73% -5.11% -0.29% -1.74% -1.67% -1.60% -2.45%

Financials Breakdown Chart

Key Financial Trends

Axe Compute’s Q2 2026 statements show a business in transition: revenue accelerated sharply and the company invested heavily in property and equipment, but profitability remains deeply negative and operating cash flow was supported primarily by working-capital movements rather than earnings.

Revenue increased to $3.2 million in Q2 2026 from just $35,000 in Q1 2026 and $2,682 in Q2 2025. Gross profit was $201,653, representing a narrow 6.3% gross margin. This is a significant improvement from the negative gross margins reported in Q2 and Q3 2025, although the sequential volatility makes it difficult to determine whether the improvement is sustainable.

Despite the revenue growth, operating expenses remained substantial. Total operating expenses reached $17.5 million, including $13.1 million in other operating expenses. As a result, Axe Compute reported an operating loss of $17.3 million and a net loss of $17.2 million, or $0.87 per basic share. The Q2 loss was more than double the $7.7 million loss recorded in Q1 2026.

The balance sheet strengthened during the latest quarter. Cash and equivalents rose from $6.9 million at March 31, 2026, to $21.9 million at June 30, 2026. Total assets increased to $100.4 million, driven largely by a substantial increase in net property, plant and equipment, which reached $17.3 million from only $216,856 in Q1. Total liabilities also increased sharply to $66.3 million, primarily because of $27.1 million in noncurrent deferred revenue and $34.4 million in other current liabilities.

Liquidity appears better than in prior periods, but the quality of the cash generation warrants attention. Q2 operating cash flow was positive at $21.1 million, even though the company reported a $17.2 million net loss. This result was driven mainly by a $58.4 million favorable change in operating assets and liabilities, while noncash adjustments reduced cash flow by $20.3 million. The company also spent $17.1 million on capital expenditures and raised $10.8 million through common-stock issuance.

  • Revenue momentum improved materially: Q2 2026 revenue of $3.2 million was a major increase from the minimal revenue reported in the comparable 2025 quarter.
  • Gross profitability returned: Axe Compute generated $201,653 of gross profit and a 6.3% gross margin in Q2 2026, compared with negative gross profit in several earlier quarters.
  • Cash reserves increased: cash and equivalents rose by approximately $15.0 million sequentially to $21.9 million, providing additional funding for operations and expansion.
  • Capital investment accelerated: net property, plant and equipment increased to $17.3 million, suggesting the company is building infrastructure to support its compute strategy.
  • Debt remains relatively limited: short-term debt was $413,611, small compared with total assets and substantially lower than the company’s equity financing activity.
  • Operating cash flow was positive but may not be recurring: the $21.1 million inflow was driven primarily by a $58.4 million working-capital benefit rather than operating earnings.
  • Liquidity is mixed: total current assets of $56.1 million exceeded current liabilities of $38.7 million, but approximately $30.0 million of current assets was classified as other current assets, making composition and convertibility important to monitor.
  • Losses remain substantial: the Q2 2026 net loss of $17.2 million was more than twice the Q1 loss, and the accumulated retained-earnings deficit reached $438.4 million.
  • Operating costs greatly exceed gross profit: total operating expenses were approximately 87 times gross profit in Q2, leaving the company far from sustainable operating profitability.
  • Equity financing creates dilution risk: Axe Compute raised $10.8 million through common-stock issuance during Q2 while continuing to report significant losses, suggesting additional fundraising could be needed if cash burn resumes.

Investors should focus on whether the recent revenue increase continues, whether gross margins improve beyond the low-single-digit level, and whether future operating cash flow is generated from customers rather than working-capital changes or equity financing. The supplied filings also contain historical ticker and company-name references to Predictive Oncology and POAI, as well as restated periods, so investors should verify the issuer transition and the comparability of prior-period figures before relying on long-term trend calculations.

11/22/26 12:55 PM ETAI Generated. May Contain Errors.

Predictive Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Predictive Oncology's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Predictive Oncology's net income appears to be on a downward trend, with a most recent value of -$233.10 million in 2025, falling from -$4.79 million in 2015. The previous period was -$12.66 million in 2024.

Predictive Oncology's total operating income in 2025 was -$180.92 million, based on the following breakdown:
  • Total Gross Profit: $52.66 thousand
  • Total Operating Expenses: $180.97 million

Over the last 10 years, Predictive Oncology's total revenue changed from $654.35 thousand in 2015 to $125.28 thousand in 2025, a change of -80.9%.

In the past 12 quarters, Predictive Oncology's cash and equivalents has ranged from $181.67 thousand in Q3 2025 to $147.71 million in Q3 2026, and is currently $147.71 million as of their latest financial filing in Q3 2026.

Predictive Oncology had total debt of $107.95 thousand at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Predictive Oncology's book value per share changed from 26.37 in 2015 to 14.06 in 2025, a change of -46.7%.



Financial statements for NASDAQ:POAI last updated on 11/17/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners